Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ANTI-CD20 MONOCLONAL-ANTIBODY. Found 3 abstracts

Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology. 2008 Nov;143(3):355-60.
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA. Long-term responses in patients with recurring or refractory B-Ccll non-hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007 May;109(9):1804-10.
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ANTI-CD20 MONOCLONAL-ANTIBODY

ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY rituximab PROTEIN EXPRESSION severe comorbidities or who refused treatment with radiation lesions presentations of CBCL at age 87 years from a non-related cause after 55 years of complete I-131 TOSITUMOMAB CELL LYMPHOMA APOPTOSIS cutaneous CHOP CHEMOTHERAPY if m(2) Maintenance therapy lymphoma intravenous infusions of 375 mg non-Hodgkin lymphoma time to progression (TTP) radioimmunotherapy PROGNOSTIC-SIGNIFICANCE MILD SYSTEMIC THERAPY cutaneous site of large-cell lymphoma that developed after 3 years in m(2) once every 2-3 months Objective PATTERN tiuxetan FOLLICULAR-GROWTH DENDRITIC CELLS either primary CBCL or low-grade effective in treating of CBCL TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be ELDERLY-PATIENTS FOLLICULAR LYMPHOMA contraindicated or unwanted Additional collaborative studies are remission One patient received local radiotherapy to a solitary lymphomas with relapses limited to the skin Rituximab appears to non-Hodgkin lymphoma (NHL) THROMBOCYTOPENIA recurrent B-cell NHL each with either extensive established We treated five patients with rituximab given as a single agent for four weekly therapy B cell 19 ongoing complete clinical remissions with a median follow-up of 17 oblimersen sodium remission from the low-grade CBCL present an attractive alternative when radiation therapy is CYTOTOXIC T-CELLS EORTC CLASSIFICATION CYCLOPHOSPHAMIDE was given at 375 mg initiated LOW-GRADE RADIOIMMUNOTHERAPY FOLLOW-UP clinical responses occurred in all five patients Three patients have PHASE-II CHRONIC LYMPHOCYTIC-LEUKEMIA EFFICACY no recurrences of either grade CBCL have yet occurred Treatment was well tolerated Rituximab is safe and NON-HODGKINS-LYMPHOMA Y-90 ibritumomab needed to assess the role of rituximab in various clinicopathologic and 39 months post achievement of complete remission One patient died
Last updated on Sunday, July 05, 2020